Advertisement

Topics

Baro-Therapies, Inc. Company Profile

17:51 EST 11th December 2018 | BioPortfolio


News Articles [256 Associated News Articles listed on BioPortfolio]

Zum zweiten Geburtstag knackt JPMorgan Investment Funds - Global Income Conservative Fund die Milliardengrenze

Frankfurt (www.fondscheck.de) - Im anhaltenden Niedrigzinsumfeld sind mehr als zwei Drittel der deutschen Sparer unzufrieden mit den Erträgen ihrer Spareinlagen. Dies zeigt das aktuelle Income-Baro.....

CAR T-Cell Therapies Show Durable Responses, New Research Also Explores Combination Therapies ...

SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Chimeric antigen receptor (CAR) T-cell therapies have quickly shifted the treatment paradigm for many people with several types Read more...

Opportunity remains in oncology for gene therapies, says GlobalData

Small pharma leads the way in cancer gene therapies Gene therapies combine reduced treatment duration with a higher chance of...Read More... The post Opportunity remains in oncology for gene therapies...

CAR T-Cell Therapies Moving to Outpatient Setting

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the o...

PhRMA Highlights Impact of Cell and Gene Therapies in New Report

This morning the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that shows there are nearly 300 novel cell and gene therapies currently in development throughout the in...

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend and enhance treatment responses

Chimeric antigen receptor (CAR) T-cell therapies have quickly shifted the treatment paradigm for many people with several types of aggressive blood cancers, in whom treatment options have been woefull...

ACT resistance will spur the uptake of novel malaria therapies

Today, artemisinin-based combination therapies (ACTs) are the first-line drugs used to treat malaria across Asia and Africa, the areas of...Read More... The post ACT resistance will spur the uptake of...

An overview of the gene therapies in development for CVMD

Gene therapies have been a point of discussion during the last several years as a potential curative option for a...Read More... The post An overview of the gene therapies in development for CVMD appe...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Hepsera [Excella GmbH]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Hepsera [Gilead Sciences, Inc.]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Olay total effects uv moisturizer [Procter & Gamble Manufacturing Company]

OLAY total effects

PubMed Articles [555 Associated PubMed Articles listed on BioPortfolio]

Emerging therapies for mitochondrial diseases.

For the vast majority of patients with mitochondrial diseases, only supportive and symptomatic therapies are available. However, in the last decade, due to extraordinary advances in defining the cause...

Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies.

Mind-body therapies: Connecting the parts and embracing diversity.

Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.

Recent advances in targeted therapies have raised expectations that the clinical application of biomarkers would improve patient's health outcomes and potentially save costs. However, the cost-effecti...

Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.

Although high upfront costs for the high value of gene therapy have resulted in concerns about sufficient reimbursement to allow patient access to these therapies, the significant benefits of gene the...

Clinical Trials [1672 Associated Clinical Trials listed on BioPortfolio]

Low Intensity Exercise in Different Normobaric/Hypobaric Normoxic/Hypoxic Conditions.

The main goal of this project is to investigate how low intensity cycling exercise (1.5W/kg, for 6 minutes) influences cerebral functions, such as: Cerebral blood flow, oxygenation, and ot...

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therap...

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

The proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (CAM) therapies to understand the selection of patients and CAM ther...

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for wh...

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment wi...

Companies [877 Associated Companies listed on BioPortfolio]

Baro-Therapies, Inc.

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

MolMed S.p.A.

Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is an integrated company covering all functions, from di...

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including: ...

Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompa...

More Information about "Baro-Therapies, Inc." on BioPortfolio

We have published hundreds of Baro-Therapies, Inc. news stories on BioPortfolio along with dozens of Baro-Therapies, Inc. Clinical Trials and PubMed Articles about Baro-Therapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Baro-Therapies, Inc. Companies in our database. You can also find out about relevant Baro-Therapies, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record